A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
NCT03619850
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
Primary Objectives: To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA Secondary Objective: To determine the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) profile of ferumoxytol in pediatric subjects.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Chronic Kidney Disease; Iron Deficiency Anemia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 2 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Last updated on ClinicalTrials.gov
- April 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Missouri · 1
- Children's Mercy Hospital · Kansas City, MO
New York · 1
- Montefiore Medical Center (MMC) - The Children's Hospital at Montefiore (CHAM) · The Bronx, NY
Ohio · 1
- Akron Nephrology Associates, Inc. · Akron, OH
West Virginia · 1
- West Virginia University · Morgantown, WV
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.